Know Labs, Inc. Study Validates Technical Feasibility of Its Novel Sensor for Non-Invasive Glucose Monitoring
May 05, 2023 at 02:00 pm
Share
Know Labs, Inc. announced the results of its latest technical feasibility study titled, "Technical Feasibility of a Novel Sensor for Non-Invasive Blood Glucose Monitoring Compared to Dexcom G6®. From December 2022 through February 2023, Know Labs conducted a series of internal studies to validate the technical feasibility of its Bio-RFID™ sensor technology at quantifying blood glucose concentration (BGC) in five healthy participants, using the Dexcom G6® as a reference device. Bio-RFID is a novel platform technology using electromagnetic energy in the form of radio waves to non-invasively capture molecular signatures and convert them into physiologically meaningful information.
The purpose of this technical feasibility study was to demonstrate hardware and software infrastructure stability, and to collect additional data to determine the accuracy of the sensor at quantifying BGCin vivo non-invasively using radio frequency, by means of training a neural network (NN) model to predict readings of the Dexcom G6®® as a proxy for BGC. In the aggregate - across five individual participants, 46 tests and 92 samples, which collected 4.7 million data points per sample or roughly 430 million data points for all samples - the study resulted in a mean absolute relative difference (MARD) of 20.6% and performed with 46% of predictions within the U.S. Food and Drug Administration's (FDA) recommended limit for accuracy for new blood glucose monitors. During the data collection period, participants placed their forearms on the Bio-RFID sensor and consumed liquid D-Glucose to simulate a glucose spike.
Know Labs, Inc. is a provider of non-invasive blood glucose monitoring solutions. The Company is focused on the development and commercialization of its proprietary sensor technology utilizing radio and microwave spectroscopy. When paired with its machine learning platform, the Companyâs Bio-RFID sensor technology platform identifies and measures various material or analyte using electromagnetic energy to detect, record, identify and measure the signature of said materials or analytes. The data obtained with its sensor technology is analyzed with the Companyâs trade secret algorithms. The Company is focused on analytes relating to human health, the identification, of which provide diagnostic information and require, by their nature, clearance by the United States Food and Drug Administration. The first among those analytes is the non-invasive monitoring of blood glucose levels. Its device provides the user with real-time information on their blood glucose levels.
KNOW LABS, INC. 
